Dr. Legha is a medical oncologist at the St. Luke’s Episcopal Hospital (Houston), where he served as a Director of the Melanoma Center of the Texas Cancer Institute since 1999. Prior to joining the St. Luke’s Hospital, Dr. Legha was a Professor of Medicine at the University of Texas MD Anderson Cancer Center. During his 22 years as a member of the faculty at the MD Anderson Hospital, he specialized in the treatment of various solid tumors, including breast cancer, head and neck cancer, and melanoma/sarcoma. He is an internationally acclaimed leader in the treatment of advanced melanoma, and is credited with developing a combination chemotherapy regimen (CVD) which is currently used worldwide in this indication.
He is especially recognized for his innovations in anticancer drug Development (Phase-1 studies) with the Taxanes and the Camptothecin-based therapies for hard-to-treat cancers. His commitment to finding new treatments and dosing regimens resulted in his defining a unique bio/chemotherapy protocol that is recognized as the first treatment to produce curative results in 10% of patients with metastatic melanoma.
He serves on the Editorial Board of Melanoma Research, which is the only journal exclusively devoted to publishing clinical and laboratory research focused on this type of cancer. As a member of the World Health Organization – Melanoma Program, Dr. Legha is a frequently invited speaker at melanoma centers around the world and actively participates in international conferences devoted to research and treatment.
During his academic career, Dr. Legha has published more than 150 scientific research papers, and has contributed chapters to 36 textbooks. He is also co-editor of a popular textbook, Chemoradiation: An Integrated Approach to Cancer Treatment. This strategy for treatment of Cancer is now widely used in the treatment of multiple solid tumors.« Back to Medical Advisory Board